Xynomic Research Institute (XRI), a subsidiary of Xynomic Pharmaceuticals Holdings, has designed a series of potent RET kinase inhibitors by computer-assisted drug design, it was reported yesterday.
The company's cRET kinase inhibitors are a range of acetylene derivatives with novel and stable structures. Preliminary activity tests indicated that they showcased outstanding selectivity and inhibitory activity against TT tumour cells, and some compounds were identified as having submicromolar IC50 values in the mid- to low-nanomolar range. Further structure-activity relationship studies are presently underway to screen and receive lead compounds.
Y Mark Xu, chairman and CEO of Xynomic, said, 'XRI focuses on research and development of innovative oncology drug candidates. We have recently upgraded our infrastructure and equipment and hired additional scientists. We believe that we are now well positioned to fully leverage XRI's capacity to efficiently design and synthesise cutting edge molecules.'
XRI has already filed global patents for internally discovered pre-clinical drug candidates XP-103 and XP-104.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer